|
1
|
Moch H, Amin MB, Berney DM, Compérat EM,
Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR,
et al: The 2022 World Health Organization classification of tumours
of the urinary system and male genital organs-part A: Renal,
penile, and testicular tumours. Eur Urol. 82:458–468. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lobo J, Ohashi R, Amin M-B, Berney DM,
Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ, et
al: WHO 2022 landscape of papillary and chromophobe renal cell
carcinoma. Histopathology. 81:426–438. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shuch B, Bratslavsky G, Linehan WM and
Srinivasan R: Sarcomatoid renal cell carcinoma: A comprehensive
review of the biology and current treatment strategies. Oncologist.
17:46–54. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thoenes W, Störkel S and Rumpelt HJ: Human
chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl
Mol Pathol. 48:207–217. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bian L, Duan J, Wang X, Yang Y, Zhang X
and Xiao S: Sarcomatoid chromophobe renal cell carcinoma: A case
report and review of the literature. Am J Case Rep. 20:1225–1230.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brunelli M, Gobbo S, Cossu-Rocca P, Cheng
L, Hes O, Delahunt B, Pea M, Bonetti F, Mina MM, Ficarra V, et al:
Chromosomal gains in the sarcomatoid transformation of chromophobe
renal cell carcinoma. Mod Pathol. 20:303–309. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brunelli M, Eble JN, Zhang S, Martignoni
G, Delahunt B and Cheng L: Eosinophilic and classic chromophobe
renal cell carcinomas have similar frequent losses of multiple
chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this
pattern of genetic abnormality is not present in renal oncocytoma,
and this pattern of genetic abnormality is not present in renal
oncocytoma. Mod Pathol. 18:161–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo R, Luo J, Chang J, Rekhtman N, Arcila
M and Drilon A: MET-dependent solid tumours-molecular diagnosis and
targeted therapy. Nat Rev Clin Oncol. 17:569–587. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rhoades Smith KE and Bilen MA: A review of
papillary renal cell carcinoma and MET inhibitors. Kidney Cancer.
3:151–161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Turpin A, Descarpentries C, Grégoire V,
Farchi O, Cortot AB and Jamme P: Response to capmatinib in a MET
fusion-positive cholangiocarcinoma. Oncologist. 28:80–83. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu XW, Chen XR, Rong YM, Lyu N, Xu CW,
Wang F, Sun WY, Fang SG, Yuan JP, Wang HJ, et al: MET exon 14
skipping mutation, amplification and overexpression in pulmonary
sarcomatoid carcinoma: A multi-center study. Tranl Oncol.
13:1008682020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amendolare A, Marzano F, Petruzzella V,
Vacca RA, Guerrini L, Pesole G, Sbisà E and Tullo A: The
underestimated role of the p53 pathway in renal cancer. Cancers
(Basel). 14:57332022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bi M, Zhao S, Said JW, Merino MJ, Adeniran
AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, et al:
Genomic characterization of sarcomatoid transformation in clear
cell renal cell carcinoma. Proc Natl Acad Sci USA. 113:2170–2175.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carlsen L, Zhang S, Tian X, De La Cruz A,
George A, Arnoff TE and El-Deiry WS: The role of p53 in anti-tumor
immunity and response to immunotherapy. Front Mol Biosci.
1:11483892023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwiatkowski DJ, Choueiri TK, Fay AP, Rini
BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L,
Agarwal N, et al: Mutations in TSC1, TSC2, and MTOR are associated
with response to rapalogs in patients with metastatic renal cell
carcinoma. Clin Cancer Res. 22:2445–2452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giraud JS, Bièche I, Pasmant É and
Tlemsani C: NF1 alterations in cancers: Therapeutic implications in
precision medicine. Expert Opin Investing Drugs. 32:941–957. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Recondo G, Che J, Jänne PA and Awad MM:
Targeting MET dysregulation in cancer. Cancer Discov. 10:922–934.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng W, Xu T, Yang L, Yan N, Yang J and
Fang S: Dramatic response to crizotinib through MET phosphorylation
inhibition in rare TFG-MET fusion advanced squamous cell lung
cancer. Oncologist. 30:oyae1662025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nandagopal L, Sonpavde GP and Agarwal N:
Investigational MET inhibitors to treat renal cell carcinoma.
Expert Opin Investig Drugs. 28:851–860. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goodman AM, Piccioni D, Kato S, Boichard
A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller
V, et al: Prevalence of PDL1 amplification and preliminary response
to immune checkpoint blockade in solid tumors. JAMA Oncol.
4:1237–1244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thompson RH, Kuntz SM, Leibovich BC, Dong
H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H,
et al: Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res.
66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawakami F, Sircar K, Rodriguez-Canales J,
Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba
II, Wood CG and Karam JA: Programmed cell death ligand 1 and
tumor-infiltrating lymphocyte status in patients with renal cell
carcinoma and sarcomatoid dedifferentiation. Cancer. 123:4823–4831.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McGregor B, Mortazavi A, Cordes L, Salabao
C, Vandlik S and Apolo AB: Management of adverse events associated
with cabozantinib plus nivolumab in renal cell carcinoma: A review.
Cancer Treat Rev. 103:1023332022. View Article : Google Scholar : PubMed/NCBI
|
